Phase II study of VcR-CVAD [bortezomib, rituximab, cyclophosphamide, doxorubicin, vincristine, dexamethasone] with rituximab consolidation and maintenance for untreated mantle cell lymphoma

Trial Profile

Phase II study of VcR-CVAD [bortezomib, rituximab, cyclophosphamide, doxorubicin, vincristine, dexamethasone] with rituximab consolidation and maintenance for untreated mantle cell lymphoma

Completed
Phase of Trial: Phase II

Latest Information Update: 22 Jun 2016

At a glance

  • Drugs Bortezomib (Primary) ; Rituximab (Primary) ; Cyclophosphamide; Dexamethasone; Doxorubicin; Vincristine
  • Indications Mantle-cell lymphoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 12 May 2016 Status changed from active, no longer recruiting to completed.
    • 16 Jun 2015 Planned End Date changed from 1 Nov 2013 to 1 Aug 2015.
    • 19 Jan 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top